Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Researchers led by Anthony Jack find evidence for dual-process theory
- Law’s Michael Benza sounds off on duration of fraud case against Browns owner’s company
- School of Medicine’s Neil Korman discusses skin condition of Canadian former finance minister
- CWRU names Yale’s Amy Backus athletic director
- Political science’s Karen Beckwith is lead editor on new book series